Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  Type 1 DiabetesIssue 613

Autoantigen Treatment Benefits Type 1's

Autoantigen treatment of new-onset type 1 diabetes was unsuccessful in preserving pancreatic beta-cell function overall, but the treatment did appear to help in certain prespecified patient subgroups....


According to Johnny Ludvigsson, MD, PhD, from Linköping University in Linköping, Sweden, and colleagues, patients given the autoantigen glutamic acid decarboxylase (GAD) had similar declines in insulin secretion as measured by stimulated C-peptide levels as did patients given placebo, with an estimated treatment ratio of 1.16 (95% CI 0.97 to 1.40, P=0.10). Males, however, had a 41% greater preservation of C-peptide, with an estimated treatment ratio of 1.41 (95% CI 1.09 to 1.83, P=0.01), the researchers reported.

Dr. Ludvigsson stated that, "Instead of saying that this study shows that we should abandon GAD and autoantigen treatment, I think the result supports the concept that GAD can be used to preserve residual insulin secretion, although we need to learn more about dosing, intervals, and which groups of patients will have the best effect." 

The use of autoantigens in type 1 diabetes is based on the hypothesis that induction of immune tolerance could stop the autoimmune process of pancreatic beta-cell destruction.

In a previous study that included 70 patients, Ludvigsson's group found that treatment with the 65-kD isoform of GAD preserved fasting C-peptide levels for more than two years and stimulated levels for 15 months, indicating residual insulin secretion. So they conducted a nine-country randomized trial that enrolled 327 patients ages 10 to 20 within three months of being diagnosed with type 1 diabetes.

Patients were randomized to receive subcutaneous injections of 20 µg GAD65 formulated with alum at baseline, one month, three months, and nine months; injections at one and three months plus two placebo injections; or four injections of placebo.

Patients in the two active treatment groups showed increases in levels of GAD autoantibodies by three months that were significantly higher than in the placebo group (P<0.001).

As with the primary endpoint of stimulated C-peptide levels at 15 months, there were no significant differences compared with placebo on various secondary endpoints, including change in fasting C-peptide (P=0.07), change in daily insulin dose (P=0.57), and change in glycated hemoglobin (P=0.86).

However, the investigators also performed multiple exploratory analyses to identify potential treatment effects in patient subgroups, and found differences not only according to sex, but also for insulin requirements, degree of maturation, and location.

Among patients whose baseline insulin dose was 0.398 to 0.605 IU/kg per day, the estimated treatment ratio was 1.33 (95% CI 1 to 1.78, P=0.05). For those whose baseline Tanner stage was 2 or 3, the ratio in the four-dose group was 1.52 (P=0.04), and the ratio for the more southern countries such as Italy and Spain was 1.36 (P=0.04), the researchers reported.

Adverse events were similar in the treatment and placebo groups, and there were no cases of stiff person syndrome, a neurologic disorder associated with high GAD65 levels.

In discussing why the results of this study contradicted those seen in the earlier trial, the investigators explained that there may have been differences in the study population or in participating clinicians' traditional treatment approaches.

Seasonal factors also may have contributed, because patients who began treatment in the spring seemed to fare better, and an outbreak of influenza with widespread immunization also may have influenced the results. In addition, the treatment groups included more patients ages 10 and 11, while the placebo group included greater numbers of 16-to-20 year olds.

Ludvigsson added that, "Nobody would expect to use one single drug in one single type of dosing for treatment of all types of cancer in all ages, so why would we believe that all type 1 diabetes in all ages, genders, and countries should be treated with just one design?"

"Much as treatments for childhood cancer and immunotherapy of allergy have developed in a stepwise, gradual manner through the combination of existing therapies, treatment for type 1 diabetes will most likely be based on the knowledge gained from this and other studies, as well as future studies, of single agents and combination therapies for both intervention and prevention," he and his co-investigators concluded.

Practice Pearls:
  • This multicenter study found no effect of the autoantigen glutamic acid decarboxylase on insulin secretion at 15 months in type 1 diabetics enrolled within three months of diagnosis.
  • Insulin secretion does appear better preserved in certain subgroups, such as males, younger children, those living in more southern climates, and those taking lower baseline doses of insulin.

Ludvigsson J, et al "GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus" New Engl J Med 2012; 366: 433-442.



Bookmark and Share | Print | Category | Home

This article originally posted 15 February, 2012 and appeared in  Type 1 DiabetesIssue 613

Past five issues: Diabetes Clinical Mastery Series Issue 251 | Issue 791 | Diabetes Clinical Mastery Series Issue 250 | GLP-1 Special Editions July 2015 | Issue 790 |

2015 Most Popular Articles:

Self-Monitoring of Blood Glucose: The Patient's Perspective
Posted July 10, 2015
Diet That Mimics Fasting Appears to Slow Aging
Posted July 03, 2015
The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Weight Reduction
Posted July 10, 2015
Important Advances in Type 1 Diabetes Research
Posted June 25, 2015
Vitamin D3 Supplementation and Weight Loss Prevent Cancer in Older Women
Posted July 10, 2015
Evaluation of Cellphone Application that Records Readings from Glucometer
Posted July 10, 2015
Can the Insulin Patch Become a Reality?
Posted July 03, 2015
New Evidence Suggests Pioglitazone Reduces Dementia Risk 42%
Posted July 03, 2015
Metformin May Increase Mortality in Advanced CKD among Type 2 Patients
Posted July 10, 2015
Liraglutide Reducing Postprandial Hyperglycemia Using Closed Loop System
Posted June 25, 2015

Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Would you be interested in a urine test strip product that measures microalbumin and creatinine levels to determine kidney failure risk in your patients?

CME/CE of the Week
Presented by CardioCareLive
Category: Cardiology